Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vemurafenib - Roche

Next Previous
Drug Profile

Vemurafenib - Roche

Alternative Names: PLX-4032; R-7204; RG-7204; RO-5185426; Zelboraf

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Chugai Pharmaceutical; Genentech; Georgetown University; H. Lee Moffitt Cancer Center and Research Institute; Kechow Pharma; M. D. Anderson Cancer Center; Melanoma Research Alliance; Memorial Sloan-Kettering Cancer Center; Plexxikon; Roche; University College London; University Hospital Tubingen
  • Class 2 ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Immunological disorders
  • Phase II Brain metastases; Colorectal cancer; Haematological malignancies; Multiple myeloma; Non-small cell lung cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 23 Aug 2023 Kechow Pharma plans a phase III trial in Colorectal cancer (Combination therapy, Metastatic disease, Second line therapy or greater) (PO), in November 2023 (NCT06008119)
  • 02 Jun 2023 Efficacy data from a phase II trial in Malignant melanoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 13 Apr 2023 Roche completes a phas II trial in Brain metastases (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in Brazil, Germany, Spain, France, Hungary, Italy, Latvia and Switzerland (PO)(NCT03625141) (EudraCT2018-000759-41)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top